Home

Intelligence

Services

Subscriptions

News

About Us

Sign In

 

Document Preview

Collaboration and License Agreement

 

Click "Add to Cart" button to purchase document. 
Documents are emailed immediately after purchase. 
You can also browse documents by
title, category, or company... or click here for help finding documents.

 

Title:

Collaboration and License Agreement

Entities:

Abgenix, Inc.; AstraZeneca plc; Astrazeneca UK Ltd.; Cell Genesys, Inc.; ImmunoGen, Inc.; Lexicon Genetics, Inc.

Date:

2004

Size:

537KB total

Price:

$99

ID:

#243874

 

 

► Licensing ► Licenses ► Collaboration & License Agreements
► Biotechnology & Drugs
► Biotech & Drugs ► Pharmaceutical Preparations
► Biotech & Drugs ► In Vitro & In Vivo Diagnostic Substances
► Biotech & Drugs ► Biological Products

 

 

Start of Preview


 

CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED.

 

 

COLLABORATION AND LICENSE AGREEMENT

 

 

BY AND BETWEEN

 

 

ABGENIX, INC.

 

 

AND

 

 

ASTRAZENECA UK LTD

 

 

DATED AS OF OCTOBER 15, 2003

 



 

TABLE OF CONTENTS

 

1.

DEFINITIONS

 

 

 

 

 

2.

RESEARCH PROGRAM

 

 

2.1

General

 

 

2.2

Collaboration Antigen Designation

 

 

2.3

Conduct of Research Program

 

 

2.4

Records

 

 

2.5

Reports and Notices

 

 

2.6

Identification of Candidate Drugs

 

 

2.7

Research Program Term

 

 

2.8

Project Leaders

 

 

2.9

Key Positions

 

 

 

 

 

3.

RESEARCH MANAGEMENT COMMITTEE

 

 

3.1

Composition of the Committee

 

 

3.2

Meetings

 

 

3.3

Purpose of Committee

 

 

3.4

Areas of Responsibility

 

 

3.5

Minutes

 

 

3.6

Disputes

 

 

3.7

Target Review Committee

 

 

 

 

 

4.

LICENSES/GRANTS OF RIGHTS

 

 

4.1

Collaboration Antigens

 

 

4.2

Research and Development Program Licenses

 

 

4.3

Licensed Products

 

 

4.4

Non-Licensed Products

 

 

4.5

Discontinued Antigens

 

 

4.6

Antigen-Specific Technology

 

 

4.7

Other Technology

 

 

4.8

Oncology Technology

 

 

4.9

Development Program Technology

 

 

4.10

Failed Antigens

 

 

4.11

Cross Licenses

 

 

4.12

Diligence

 

 

4.13

Distributors

 

 

4.14

Covenant Not to Sue

 

 

4.15

Covenant by ABX

 

 

4.16

Covenant by AZ

 

 

4.17

Third Party Rights

 

 

4.18

Further Covenants and Agreements

 

 

4.19

Trademarks

 

 

4.20

Certain Restrictions and Rights Regarding Failed and Discontinued Antigens

 

 

i



 

5.

DEVELOPMENT PROGRAM

 

 

5.1

General

 

 

5.2

Conduct of Development

 

 

5.3

Development Program Work Plan and Budget

 

 

5.4

Process Development Program

 

 

5.5

Records

 

 

5.6

Reports and Notices

 

 

5.7

ABX Registrations

 

 

5.8

AZ Registrations

 

 

5.9

Election Notice

 

 

5.10

Non-Licensed Products

 

 

5.11

Right to Abandon

 

 

5.12

Development Program Leaders

 

 

5.13

Performance of Development Program by AZ

 

 

5.14

Term of Development Program

 

 

 

 

 

6.

DEVELOPMENT MANAGEMENT COMMITTEE

 

 

6.1

Composition of the Committee

 

 

6.2

Meetings

 

 

6.3

Purpose of Committee

 

 

6.4

Areas of Responsibility

 

 

6.5

Minutes

 

 

6.6

Disputes

 

 

 

 

 

7.

PROCESS SCIENCE AND MANUFACTURING

 

 

7.1

Negotiation and Execution of Agreements

 

 

7.2

Prior to First Commercial Sale

 

 

7.3

Manufacture of Licensed Product for Commercial Sale

 

 

7.4

Manufacturing Commitment and Capacity

 

 

7.5

Failure or Inability to Perform

 

 

7.6

Additional Capacity or Technologies

 

 

7.7

Manufacturing and Supply Committee

 

 

7.8

Information Disclosure

 

 

7.9

Process Technology

 

 

7.10

Technology Transfer

 

 

7.11

Disengagement

 

 

7.12

DMF

 

 

7.13

Process Development Funding and Supply Price

 

 

7.14

Termination

 

 

7.15

Use of Technologies

 

 

 

 

 

8.

CO-DEVELOPMENT AND COMMERCIALIZATION

 

 

8.1

Co-Development Agreement

 

 

8.2

Offer